常山藥業(300255.SZ):目前的艾本那肽三期臨牀試驗,適應症為2型糖尿病
格隆匯5月15日丨有投資者在投資者互動平台向常山藥業(300255.SZ)提問,“貴司的艾本那肽現在進度如何?是否有減肥效果?有沒有計劃用於醫美減肥領域?”
常山藥業回覆稱,公司的1.1類原研創新藥艾本那肽三期臨牀試驗,受試者已經全部出組,目前正在推進三期臨牀試驗的數據清理、統計分析、總結報吿等後期工作。目前的艾本那肽三期臨牀試驗,適應症為2型糖尿病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.